# Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli

> **NCT02142751** · PHASE3 · COMPLETED · sponsor: **Fundación Pública Andaluza para la gestión de la Investigación en Sevilla** · enrollment: 161 (actual)

## Conditions studied

- Infection Due to ESBL Escherichia Coli

## Interventions

- **DRUG:** Fosfomycin sodium intravenous
- **DRUG:** Meropenem intravenous
- **DRUG:** Ceftriaxone intravenous

## Key facts

- **NCT ID:** NCT02142751
- **Lead sponsor:** Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2018-12
- **Final completion:** 2019-03
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2019-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02142751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02142751, "Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02142751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*